hitt on tour
health & around thoughts, on the fly & on the flight
New acquisition cost of Repatha
Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.
Gene therapy: Will it deliver its commercial promise?
On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”
Drugs in the graveyard increase costs
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!
Health Literacy, the resist subject
What is Health Literacy?
Apps in Africa? Yes, but…
Sometimes, when we think about a new app or technology that will be useful for improving health in African people, we don’t consider the applicability that this app will have.
Innovative public purchase
The last two months HiTT has been working in 2 different projects of innovative public purchase, this week we finally have present them to the regional health service call.
